The healthcare sector is one of the largest and most complex in the world, spanning a diverse range of industries, such as drug manufacture, medical equipment, health insurance, healthcare facilities (e.g. clinics and hospitals) and so on.
Deloitte anticipates global healthcare expenditures to continue to rise alongside spending, which is projected to increase at 5.4% a year between 2017 and 2022, growing from $7.7trln to $10trln. With ageing populations, chronic diseases prevailing and the exponential growth of often costly digital innovations, the value of healthcare is only likely to go up.
Why invest in healthcare?
Advances in healthcare offer great potential to the UK's health service. The problem? It can be difficult for these opportunities to secure investment since they can take many years of R&D to hit the market. Meanwhile, the prevalence of non-communicable diseases such as cancer, heart disease and diabetes continues to climb. Investors have a unique opportunity to help shape the healthcare landscape when they invest in startups that push the boundaries of medical science.
The only way to meet the growing demands of the sector is to facilitate innovative new treatments and infrastructure through technology, making global healthcare more sustainable. That's where the opportunity for versatile young businesses – and the investors that can make them happen – comes in.
If you're an investor who is happy to wait seven-plus years for any return so long as your investment has the potential to improve people's lives for generations to come, healthcare might be the sector for you.
Why invest with SyndicateRoom?
Today, 33% of the businesses that seek funding through our platform fall into this category (2019). This trend is due in large part to the fact that the investors that use SyndicateRoom tend to be hunting for long-term investments with the potential to make a significant difference worldwide – in simple terms, ones that want to make the world a better place.
Some recent healthcare startups we backed are Camallergy, a business developing life-changing treatments for people with food allergies, starting with peanuts; PatientSource, software that enables medical records to be stored electronically; MGB Biopharma, a business developing a new class of anti-infective medicine.
Why invest with SyndicateRoom?
Our Access EIS fund builds a diversified startup portfolio for you by co-investing with experienced angel investors. It aims to build a portfolio of at least 50 companies for each investor to further mitigate risk, and to replicate annual market growth in the UK startup sector.
What SyndicateRoom offers:
A data-driven approach to venture capital investing that aims to minimise risk.
Access to a larger portion of the startup market through co-investment with experienced business angels.
Generous tax reliefs as part of the EIS scheme for qualifying investors.
Low minimum investment of £5,000.
SyndicateRoom is FREE to join
With SyndicateRoom you gain access to invest alongside professional investors receiving the same share class and same share price.